middle.news
How Arovella’s FDA Feedback Accelerates Its CAR-iNKT Therapy Launch
8:54am on Tuesday 28th of October, 2025 AEDT
•
Biotechnology
Read Story
How Arovella’s FDA Feedback Accelerates Its CAR-iNKT Therapy Launch
8:54am on Tuesday 28th of October, 2025 AEDT
Key Points
Positive FDA Type D meeting outcome on reagent testing
IND application for ALA-101 expected before end of 2025
ALA-101 targets CD19+ B cell lymphomas and leukemias
Dual targeting via CAR and invariant T cell receptor
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ALA
OPEN ARTICLE